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Abstract
Engagement of the CD3/T cell receptor complex in systemic lupus erythematosus (SLE) T cells involves Syk rather
than the zeta-associated protein. Because Syk is being considered as a therapeutic target we asked whether Syk is
central  to  the  multiple  aberrantly  modulated  molecules  in  SLE  T  cells.  Using  a  gene  expression  array,  we
demonstrate that forced expression of Syk in normal T cells reproduces most of the aberrantly expressed molecules
whereas silencing of Syk in SLE T cells normalizes the expression of most abnormally expressed molecules. Protein
along with gene expression modulation for select molecules was confirmed. Specifically, levels of cytokine IL-21, cell
surface  receptor  CD44,  and  intracellular  molecules  PP2A  and  OAS2  increased  following  Syk  overexpression  in
normal T cells and decreased after Syk silencing in SLE T cells. Our results demonstrate that levels of Syk affect the
expression of a number of enzymes, cytokines and receptors that play a key role in the development of disease
pathogenesis in SLE and provide support for therapeutic targeting in SLE patients.
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Introduction
Following recognition of an antigen on the surface of a major
histocompatibility complex (MHC) molecule, the T cell receptor
(TCR) initiates a number of signaling cascades that determine
cytokine  production,  cell  survival,  proliferation  and
differentiation.  The  initial  event,  phosphorylation  of
immunoreceptor  tyrosine-based  activation  motifs  (ITAMs)  on
the cytosolic side of the TCR/CD3ζ chain complex, allows for
Zap70  (ζ-chain  associated  protein  kinase)  to  be  recruited  to
CD3ζ. Zap70 becomes activated in this way and promotes the
recruitment  and  phosphorylation  of  other  adaptor  molecules
responsible of transmitting signals downstream.
Several studies have shown that TCR signaling is modified in
patients suffering from SLE [1,2]. Instead of transmitting signals
through  TCR  to  CD3ζ  and  Zap70,  an  alternative  pathway
comes  into  play  involving  FcRγ  and  spleen  tyrosine  kinase
(Syk) [3,4]. FcRγ is homologous in shape and function to CD3ζ
and  takes  its  place  in  SLE  T  cells  [5,6]  and  associates  with
Syk. This alternative FcRγ/Syk duet is 100 times enzymatically
more  potent  than  the  canonical  CD3ζ/Zap70.  As  a  result,
following activation, SLE T cells exhibit higher intracytoplasmic
calcium  flux  and  cytosolic  protein  tyrosine  phosphorylation
[7,8].
To better understand the contribution of Syk in the aberrant
phenotype of SLE T cells we examined the effect of Syk on the
expression  of  molecules  known  to  contribute  to  the
pathogenesis of SLE. A two-step approach was followed: (a)
Syk  was  overexpressed  in  healthy  blood-donor  T  cells  to
examine  whether  increased  Syk  expression  creates  SLE-like
phenotype; and (b) Syk was downregulated, using siRNA, in
SLE T cells to examine whether gene expression abnormalities
can  be  corrected.  Our  results  show  that  Syk  contributes
significantly  to  the  abnormal  expression  of  a  number  of
molecules associated with the immunopathogenesis of SLE.
Materials and Methods
Ethics statement and blood samples
This study was approved by the Institutional Review Board of
Beth  Israel  Deaconess  Medical  Center  (BIDMC).  Written
informed consent was obtained from all participating subjects
and  all  clinical  investigation  was  conducted  according  to  the
principles  expressed  in  the  Declaration  of  Helsinki.  Blood
samples  were  obtained  from  21  SLE  patients  attending  the
Rheumatology Division of BIDMC and 14 healthy blood donors
from the Dana-Farber Cancer Institute. All participating patients
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e74550fulfilled at least 4 out of 11 criteria for SLE as set forth by the
American College of Rheumatology [9]. Patient characteristics
are  shown  in  Table  1.  In  each  experiment  samples  from
different patient or healthy control blood donors were used. The
disease  activity  of  the  patients  was  determined  using  the
Systemic Lupus Erythematosus Activity Index (SLEDAI) [10].
Cells, reagents and antibodies
Total T cells were purified using the Rosette Sep T cell kit
(StemCell  Technologies,  Vancouver,  Canada).  Blood  was
incubated  with  a  purification  mixture  that  contains  antibodies
against CD14, CD16, CD19, CD56 and glyA and attaches non-
T  cells  to  erythrocytes.  Lymphocyte  separation  medium
(Cellgro, Manassas, VA) was subsequently used to separate
these complexes from T cells.
For flow cytometry the following antibodies were used: SYK-
PE from Santa Cruz Biotechnology (Santa Cruz, CA), CD3-PB
from  Biolegend  (San  Diego,  CA),  CD44v3-APC  from  R&D
systems  (Minneapolis,  MN),  CD44v6-FITC  from  Abcam
(Cambridge,  MA)  and  IL-21-AlexaFluor647  from  BD
Pharmingen (San Jose, CA).
For western blot the following antibodies were used: OAS2
from  Proteintech  (Chicago,  IL),  PP2A  C  subunit  from  Cell
Signaling (Boston, MA), β-actin from Sigma-Aldrich (St. Louis,
MO) and anti-rabbit HRP-conjugated secondary antibody from
Santa Cruz Biotechnology (Santa Cruz, CA).
Plasmid and siRNA transfections
Transient  transfections  of  human  T  cells  were  carried  out
using  the  Lonza  Nucleofector  system  (Lonza,  Cologne,
Germany). Briefly, 5 × 106 cells were resuspended in 100µl of
nucleofector solution, plasmid DNA (1µg/106 cells) was added,
and cells were transferred to cuvettes to be transfected using
the U-014 program. The PCMV6XL6 -SYK expression plasmid
from OriGene (Rockville, MD) was used.
For  Syk  silencing,  T  cells  were  transfected  with  15nM  of
either  control  siRNA  or  SYK-specific  siRNA  (Ambion,  Grand
Island, NY). Pre-designed and validated siRNA was purchased
from  Applied  Biosystems  (Grand  Island,  NY):  SYK  siRNA,
sense,  CGCUCUUAAAGAUGAGUUATT,  and  antisense,
UAACUCAUCUUUAAGAGCGGG.
Following  transfections,  cells  were  rescued  immediately  in
prewarmed RPMI medium supplemented with 10% fetal bovine
serum  and  1%  penicillin  and  streptomycin  in  24-well  culture
plates.
RNA isolation and reverse transcription
Three million cells were lysed in RLT buffer and RNA was
extracted using Qiagen (Valencia, CA) RNeasy extraction kit. A
Table 1. Patient characteristics.
SLEDAI mean ±SEM: 2 ±1 (range: 0-9)
Sex 95% female
Race 50% black; 35% white; 10% mixed; 5% asian
Age mean ±SEM: 47 ±2 (range: 32-60)
DNase-I treatment step (Qiagen) was added to the standard
protocol  to  ensure  exclusion  of  genomic  DNA  from  the  final
product. OD260/280 measurements were used as a measure of
quality of isolated RNA. T cell derived total RNA was reversely
transcribed into cDNA using Promega (Madison, WI) reverse
transcription  system  and  a  mixture  of  1:10  oligo  (dT)20  to
random hexamer primers. Reverse transcription was performed
in a conventional thermocycler.
Real-time PCR
Quantitative  real  time  polymerase  chain  reaction  (rtPCR)
was performed to measure gene expression levels using UPL
probes (Universal Probe Library) from Roche (Indianapolis, IN).
A reaction mixture of a total volume of 10µl was prepared in a
final  concentration  of  200nM  for  each  primer,  100nM  for  the
probes,  1x  LightCycler  480  Probes  Master  and  cDNA.  All
reagents  were  obtained  from  Roche  (Indianapolis,  IN)  apart
from  High  Purity  Salt  Free  (HPSF)  primers  obtained  from
Eurofins  MWG  Operon  (Huntsville,  AL).  Reactions  were
prepared in 96 well plates and amplification was performed on
a Roche LightCycler 480 PCR instrument (Roche, Indianapolis,
IN).  Detailed  information  on  the  primers  and  probes  used  is
given in Table S1.
Crossing  points  (Ct)  were  calculated  using  the  second
derivative  maximum  method  and  expression  levels  were
normalized against two reference genes (CD3ε and GAPDH).
Ct values over 40 were excluded from the analysis.
Immunofluorescent staining
Half a million cells from each blood donor were stained ex
vivo  for  flow  cytometry  analysis.  After  harvesting,  cells  were
incubated  at  room  temperature  for  30  min  with  cell  surface
fluorochrome-conjugated  monoclonal  antibodies.  For
intracellular staining, cells were then resuspended in 100 µl of
Cytofix/Cytoperm solution (BD Biosciences, San Jose, CA) for
20 min at 4°C and washed twice in Perm/Wash solution (BD
Biosciences,  San  Jose,  CA).  After  30min  incubation  with
intracellular antibodies, cells were again washed and collected
by centrifugation at 400xg for 5 minutes.
Expression  of  cell  surface  and  intracellular  markers  was
assessed on a BD Biosciences LSRII flow cytometer, and data
were  gated  and  displayed  in  Flowing  Software  2.5  (Turku
Centre for Biotechnology, Finland).
Western blotting
Cells  were  first  pelleted  and  then  lysed  in
radioimmunoprecipitation  assay  (RIPA)  buffer  (Boston
Bioproducts, Ashland, MA). Lysates were then resolved on 4–
12%  BisTris  gels  and  transferred  to  polyvinylidene  difluoride
(PVDF)  membrane.  Membranes  were  then  blocked  with  4%
nonfat milk in Tris-buffered saline with 0.05% Tween 20 (TBS-
T)  for  1h  and  incubated  with  primary  antibody  at  room
temperature  for  1h.  After  washing  three  times  with  TBS-T
membranes were then incubated with horseradish peroxidase-
conjugated secondary antibody for 1h, washed three times and
developed  with  ECL  detection  reagents  (GE  Healthcare,
Piscataway,  NJ).  Bands  were  visualized  in  the  Fujifilm
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software (National Institutes of Health).
Analysis and statistical methods
Student’s  t-test  was  used  for  statistical  analysis.  All  plots
were constructed in Prism 5 (GraphPad, La Jolla, CA).
Results
a) Modulation of Syk expression in SLE-patient and
healthy blood-donor T cells
Although it is established that Syk is increased in SLE T cells
it  has  not  been  previously  shown  whether  increased  Syk
expression represents a primary or a secondary abnormality in
these  cells.  To  determine  this  we  first  upregulated  Syk
expression  in  healthy  blood  donor  T  cells  using  a  SYK
expression  vector.  Following  transfection  with  the  expression
vector, cells were cultured for 72h and SYK messenger RNA
(mRNA)  was  measured  using  quantitative  PCR.  Syk
overexpression resulted in significant upregulation of Syk in all
experiments performed. Average expression levels more than
doubled  in  these  cells  in  comparison  to  empty  vector
transfected  (Figure  1a).  To  examine  whether  this  finding
translates  into  higher  protein  expression  levels  as  well,  Syk
was  measured  by  flow  cytometry.  Syk  was  significantly
upregulated in those cells transfected with the SYK-expression
vector in comparison to those transfected with the empty vector
(Figure 1a).
To examine whether any of the abnormalities seen in SLE
patients  are  corrected  following  downregulation  of  SYK
expression we then used SLE patient T cells and silenced its
expression using a SYK-specific small interfering RNA (siRNA).
SYK mRNA levels were found to be significantly decreased in
SYK-siRNA transfected T cells in comparison to control siRNA
transfected ones (≥50%) (Figure 1b). Expression levels of Syk
at the protein level were also found to significantly decrease
following SYK silencing (Figure 1b). There was no correlation
between  SLEDAI  score  and  fold  Syk  change  following  SYK
silencing. These results demonstrate that SYK silencing was
successful in downregulating intracellular Syk expression at the
gene and protein levels.
b) SYK affects expression levels of genes associated
with SLE
To determine whether Syk regulates at the mRNA level the
production of cell molecules that are known to be aberrantly
expressed  in  SLE  we  used  healthy  blood  donor  T  cells  and
SYK  expression  was  artificially  induced  using  a  SYK-
overexpression vector. A panel of 36 genes known to play an
important role in aberrant SLE T cell function was chosen to be
studied.  We  chose  these  genes  because  of  their  proven
association  with  SLE  pathophysiology  and  our  own
observations that this panel of genes can reliably differentiate
between  SLE  patients  and  controls  (  [11]  and  unpublished
data). We indeed found that overexpression of SYK resulted in
upregulation of several of these molecules (Figure 2a). Most
notably, the expression of cytokine IL-21, cell surface molecule
CD44, and intracellular molecules PP2A and OAS2 were found
to  substantially  increase  in  cells  overexpressing  SYK  (fold
increase  in  SYK  overexpressing  cells  over  controls:  IL-21,
5.7±1.5;  CD44,  4.2±2.2;  PP2A,  1.5±1;  OAS2,  1.5±0.3;
normalized against GAPDH and CD3ε).
Following  the  reverse  approach,  suppression  of  Syk
expression in SLE T cells resulted in a substantial decrease in
the  expression  of  those  genes  (Figure  2b).  Specifically,
Figure 1.  Induced Syk expression and Syk silencing in T cells.  a) T cells extracted from healthy blood-donors were transfected
with either a SYK (SYK) or an empty (EV) expression vector. Following 72h of incubation, cells were lysed, RNA extracted and SYK
expression levels measured in real-time PCR. SYK overexpression led to a significant increase in its mRNA levels in all four
experiments tested (left panel, normalized expression levels shown). To investigate whether this finding translates into protein
expression levels as well, whole T cells were used to be analyzed in flow cytometry. Syk protein was found to significantly increase
following SYK overexpression in all experiments tested (right panel, a representative plot is shown, plots gated on CD3+ T cells). b)
T cells extracted from SLE patients were transfected with either a SYK-specific (siRNA) or a control (control) siRNA and expression
levels of Syk were measured using real-time PCR and flow cytometry. The SYK silencing protocol led to a significant reduction in its
expression at both the mRNA (left panel) and protein levels (right panel).
doi: 10.1371/journal.pone.0074550.g001
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found to decrease following siRNA-mediated SYK knockdown
(fold increase in SYK siRNA treated cells over controls: CD44,
-2.8±0.4;  PP2A,  -2.7±1.9;  IL-21,  -1.9±0.2;  OAS2,  -1.1±0.8,
normalized against GAPDH and CD3ε).
c) Forced SYK expression in healthy blood donor T
cells modulates expression levels of molecules
associated with the pathogenesis of SLE
To verify that changes seen at the mRNA level translate into
changes in protein expression, we measured the protein levels
of CD44, IL-21, PP2A and OAS2 following overexpression and
silencing of Syk. For CD44 in particular we measured splice
variants v3 and v6, as both are associated with SLE [12].
Overexpression of SYK in healthy blood donor T cells led to
a significant upregulation in expression of IL-21 cytokine and
CD44v6  receptor.  A  smaller  increase  in  CD44v3  expression
was also seen although overall levels of this variant were found
to be quite low (Figure 3a, empty vector vs. SYK expressing
vector  transfected  T  cells,  mean  positive  cells±SEM:  IL-21,
7.9±1 vs. 13±2.3, p=0.05; CD44v3, 2.1±0.3 vs. 2.6±0.4, p = ns;
CD44v6, 10.7±1.2 vs. 16±2.1, p=0.05).
To  evaluate  the  effect  of  Syk  forced  expression  on
cytoplasmic  molecules  PP2A  and  OAS2,  cells  were  lysed  in
RIPA buffer and subjected to Western blot. T cells transfected
Figure 2.  Intracellular levels of Syk affect the expression of genes associated with SLE immunopathogenesis.  a) Healthy
blood donor T cells were transfected with a SYK overexpression plasmid and the expression of an array of genes associated with
SLE immunopathogenesis was measured using real-time PCR. A number of genes known to be overexpressed in SLE patients
were found to be upregulated by SYK overexpression, like IL-21, CD44, OAS2 and PP2A (mean ±SEM fold expression changes
between overexpression and empty vector transfected cells in four different experiments are shown). b) SLE patient T cells were
transfected  with  either  a  SYK-specific  siRNA  or  a  control,  non-silencing,  siRNA.  Silencing  of  SYK  resulted  in  suppression  of
expression of a number of genes known to be aberrantly upregulated in SLE. Notably, expression levels of IL-21, CD44, OAS2 and
PP2A were all found to decrease in SYK-knockdown T cells (mean ±SEM fold expression changes between silencing and control
transfected T cells in four different experiments are shown).
doi: 10.1371/journal.pone.0074550.g002
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in expression of both OAS2 and PP2A in comparison to empty
vector transfected (Figure 3b, empty vector vs. SYK expressing
vector  transfected  T  cells,  mean  relative  expression±SEM,
OAS2/actin  ratio:  0.91±0.1  vs.  1.39±0.2,  p=0.05;  PP2A/actin
ratio: 0.49±0.1 vs. 1.23±0.3, p=0.05).
d) Silencing of SYK in SLE patient T cells corrects
disease-associated T cell abnormalities
We then measured protein expression of CD44v3, CD44v6,
IL-21,  PP2A  and  OAS2  in  SYK-siRNA  treated  SLE  T  cells.
Knockdown  of  SYK  resulted  in  a  significant  decrease  in
CD44v6 and IL-21 expression. Again, the decrease in CD44v3
expression  was  found  to  be  smaller  and  overall  expression
levels of this molecule quite low (Figure 4a, control vs. SYK
siRNA  transfected  T  cells,  mean  positive  cells±SEM:  IL-21,
18.6±2.4 vs. 11.4±1.6, p=0.03; CD44v3, 2.9±0.3 vs. 1.8±0.2, p
= ns; CD44v6, 11.7±0.7 vs. 7.6±1.2, p=0.05).
T  cells  in  which  SYK  had  been  silenced  also  displayed
decreased  expression  of  OAS2  and  PP2A  in  comparison  to
control  siRNA  treated  (Figure  4b,  control  vs.  SYK  siRNA
transfected  T  cells,  mean  relative  expression±SEM,  OAS2/
actin  ratio:  1.47±0.2  vs.  1.13±0.1,  p=0.03;  PP2A/actin  ratio:
1.26±0.3 vs. 0.78±0.2, p=0.05).
Figure 3.  Induced Syk expression upregulates expression levels of SLE-associated molecules in healthy blood donor T
cells.  a) SYK was overexpressed in healthy blood donor T cells using a transient nucleofection protocol and expression levels of
IL-21, CD44v3 and CD44v6 measured in flow cytometry. SYK overexpression resulted in the upregulation of the expression of all
these molecules at the protein level. Changes in expression of variant v6 of CD44 molecule seemed to account for most of the
changes seen at the mRNA level (bars show the mean ±SEM of SYK (SYK) vs. empty vector (EV) transfected T cells in ≥7
experiments). b) Following the same transfection protocol cells were lysed in RIPA buffer and subjected to western blot using
antibodies against PP2a, OAS2 and β-actin. Protein expression levels of both OAS2 and PP2a increased significantly following SYK
induced  expression.  Following  measurement  of  band  intensity  the  ratio  of  PP2a  or  OAS2  to  β-actin  was  calculated  in  each
experiment (a representative experiment and cumulative data (mean ± SEM) from 10 experiments are shown).
doi: 10.1371/journal.pone.0074550.g003
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SLE  T  cells  express  high  levels  of  Syk  and  preferentially
transmit  signals  through  FcRγ/Syk  instead  of  the  canonical
CD3ζ/  Zap70  pathway.  This  rewiring  of  the  TCR  signaling
complex  is  associated  with  profound  transcriptional
dysregulation  of  several  key  molecules  in  SLE  T  cells  [13].
Specifically,  SLE  T  cells  display  upon  activation  increased
calcium flux, tyrosine phosphorylation and actin polymerization
[14].
We have shown previously that Syk expression is controlled
by  the  transcription  factors  c-Jun  and  Ets-2  and  is
transcriptionally upregulated in SLE T cells [15] primarily due to
activated  c-Jun.  Syk  inhibition  using  siRNA  [15]  or  a  small
molecule  R406/R788  [3]  resulted  in  decrease  in  the  calcium
flux following SLE T cell activation, but had no effect on normal
T  cells.  Moreover,  Syk  inhibition  decreased  the  rapid  actin
polymerization of SLE T cells proving the importance of Syk in
SLE T cell activation. The global importance of Syk in SLE was
also shown in lupus prone mice, where treatment with R788
resulted in prevention of nephritis and dermatitis [16].
Given these findings we asked whether upregulation of Syk
in normal T cells can re-create the phenotype of SLE T cells;
and vice versa, whether downregulation of Syk can normalize
the expression of key signaling molecules in SLE T cells. We
chose to examine the expression of 39 signaling molecules that
have been linked to SLE T cell phenotype. Of those molecules,
four  were  most  profoundly  and  consistently  affected  by  Syk
overexpression  and  downregulation  (Figure  5).  Specifically,
overexpression of Syk resulted in upregulation of IL21, CD44,
Figure 4.  Silencing of SYK results in the suppression of aberrantly expressed molecules in SLE.  a) SLE patient T cells were
transfected with 15nM of either control or SYK-specific siRNA. Seventy-two hours following transfection cells were harvested and
stained with antibodies against IL-21, CD44v3 and CD44v6. Silencing of SYK resulted in the suppression of expression of all the
above molecules, particularly IL-21 and CD44v6. Bars show the mean ±SEM of control (control) vs. SYK-siRNA (siRNA) transfected
T cells in ≥7 experiments and a representative experiment is shown. b) Protein expression levels of OAS2 and PP2a measured in
western blot were found to decrease following silencing of SYK. Mean ±SEM of densitometry analyses of SYK-specific (siRNA) vs.
control (control) siRNA transfected cells in ≥6 experiments are plotted. A representative experiment and cumulative data are shown.
doi: 10.1371/journal.pone.0074550.g004
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in downregulation of these molecules. Findings were consistent
at both the mRNA and protein levels for all molecules tested.
Out of the two CD44 receptor molecule variants most highly
associated  with  SLE  (v3  and  v6)  [12]  v6  was  found  to  be
primarily affected by changes in Syk expression levels.
A number of previous studies have shown the importance of
the above molecules in SLE. IL-21, has been found to play an
important  role  in  T  cell-dependent  B  cell  differentiation  into
plasma  cells  and  the  production  of  antibodies  in  SLE  [17].
Hence Syk overexpressing SLE T cells can provide increased
help  to  B  cells  to  produce  pathogenic  autoantibodies,  a  key
feature of the disease.
Expression of CD44, a cell-surface glycoprotein involved in
cell-cell interactions and cell adhesion is increased in SLE T
cells, allowing for increased adhesion and migration [18]. CD44
splice variants v3 and v6 in particular, are upregulated in SLE T
cells and their expression correlates with disease activity [12].
T cells in kidneys of SLE patients have been found to express
CD44  suggesting  that  these  molecules  may  allow  T  cells  to
migrate abnormally into kidneys in them [19]. Therefore Syk not
only controls actin polymerization upon SLE T cell activation,
but  also  by  enhancing  CD44  expression  may  lead  to  faster
adhesion and migration of T cells to tissues. Although both v3
and v6 variants are associated with SLE, we found that mainly
variant v6 is regulated by Syk. This finding may demonstrate a
variable  role  of  Syk  in  the  expression  of  these  two  splice
variants and points towards an important role for CD44v6 in the
pathogenesis of SLE.
PP2A  (protein  phosphatase  2),  a  serine/threonine
phosphatase  that  regulates  a  number  of  cellular  processes,
plays an important role in SLE. SLE T cells express abnormally
high levels of PP2A, which leads to decreased expression of
interleukin-2 upon T cell activation [20]. As IL-2 is important for
Treg function, increased expression of PP2A may be in part
responsible for defective Treg function in SLE [21]. PP2A also
regulates the expression of CD3ζ and FcRγ, leading to TCR
rewiring [22] and further enhancing Syk recruitment to the TCR/
FcRγ  complex.  Moreover,  PP2A-transgenic  mice  display
increased expression of IL-17 and increased susceptibility to
immune-mediated  glomerulonephritis  [23].  Therefore,  Syk  by
controlling  at  least  in  part  the  expression  of  PP2A,  may
regulate the composition of TCR and tilt the balance of T cell
activation towards the pro-inflammatory Th17.
Finally,  OAS2  (2'-5'-oligoadenylate  synthetase)  is  an
interferon-induced  molecule  that  is  involved  in  the  innate
immune response towards viral infection. OAS2 activates latent
RNase  L  which  is  involved  in  the  degradation  of  viral  RNA.
Along with several other interferon-inducible molecules, OAS2
has  been  found  to  be  significantly  upregulated  in  SLE  [24].
These molecules represent the, so-called, ‘interferon-signature’
in SLE and are thought to be the result of high levels of type I
Inteferons  (IFNs)  in  these  patients.  Type  I  IFNs  play  an
important role in the promotion of inflammatory responses; they
prevent activated T-cell death and contribute to the generation
of  effector  cells  during  viral  infections  [25].  They  have  also
been  found  to  play  a  role  in  the  process  of  CD8  T  cell-
dependent generation of autoantigens [26].
Exactly how Syk affects the expression of these molecules
remains  to  be  determined.  Previous  studies  suggest  some
possible links: Syk has been found to associate with adaptor
molecules  Vav1,  phospholipase  Cγ1  (PLCγ1)  [27,28]  and
extracellular signal-regulated kinase (ERK) [29] in the process
of regulating the production of cytokines and other molecules.
Vav1 is a molecule known to activate NF-κB and, a member of
the  NF-κB  family,  c-Rel,  has  been  found  to  activate
transcription of IL-21 in T cells [30]. Finally, p38, a member of
the mitogen-activated protein kinase (MAPK) pathway (which
includes ERK) has been found to be involved in the expression
of CD44 in monocytes [31].
Figure 5.  Schematic representation of the proposed role of Syk in SLE.  Syk promotes the upregulation of a number of
cytokines, receptors and enzymes that play a key role in SLE immunopathogenesis. It affects expression levels of CD44, primarily
variant v6, involved in T cell migration; IL-21, involved in antibody production; OAS2, involved in type-I interferon responses; and
PP2A, involved in the regulation of IL-2 production.
doi: 10.1371/journal.pone.0074550.g005
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PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e74550In this study, we focused on determining the effect of Syk on
resting T cells as we have previously shown the effect of Syk
overexpression/knockdown  on  the  activation  of  T  cells  [15].
Therefore, the effect of Syk on the expression of molecules that
are produced by T cells upon activation (such as IL-2 or CD40
ligand) cannot be fully assessed.
In conclusion, our data show that overexpression of Syk in
healthy  T  cells  recapitulates  at  least  part  of  the  SLE  T  cell
phenotype. Syk overexpressing T cells may provide more help
to B cells through IL21, have enhanced migration to tissues by
upregulating  CD44  and  produce  proinflammatory  rather  than
counterinflammatory  cytokines.  Inhibiting  Syk  in  SLE  T  cells
leads  to  the  opposite  effect,  further  underscoring  Syk’s
potential as a therapeutic target in SLE.
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